Document Detail


Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.
MedLine Citation:
PMID:  21997197     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To compare the effect of an intravitreal injection of bevacizumab alone (IVB) or combined with triamcinolone (IVB/IVT) versus triamcinolone (IVT) in patients with diabetic macular edema (DME).
METHODS: In this randomized three-arm clinical trial, eligible eyes were assigned randomly to one of the three study arms: the IVB group, 2 injections of 1.25 mg of bevacizumab with 6-week intervals; the IVB/IVT group, 1.25 mg of IVB with 2 mg of IVT, and the IVT group, 2 mg of IVT. The clinical course of best-corrected visual acuity and central macular thickness by optical coherence tomography was monitored for up to 12 months after the initial injection.
RESULTS: One hundred eleven eyes of 105 patients with DME completed 12 months of follow-up. The IVB/IVT group and the IVT group showed better visual acuity and reduced central macular thickness at 6 weeks and 3 months, compared with the IVB group (p = 0.041, p = 0.02 at 6 weeks; p = 0.045, p = 0.043 at 3 months, respectively). However, no significant difference in visual acuity and central macular thickness was observed between the three groups at 12 months (p = 0.088, p = 0.132, respectively). The frequency of retreatment was lower in the IVB/IVT and IVT groups during the 12-month period (p < 0.001). No significant differences in visual acuity or central macular thickness were observed between the IVB/IVT and IVT groups during the follow-up.
CONCLUSION: IVB/IVT and IVT showed more pronounced effects during the earlier postinjection period. However, levels of visual acuity or central macular thickness at 12 months were comparable in the three study groups. No beneficial effect of the combination injection was observed.
Authors:
Ji Won Lim; Hyo Kyoung Lee; Min Cheol Shin
Related Documents :
22051867 - Endovascular treatment combined with emboloscleorotherapy for pelvic arteriovenous malf...
10655987 - Cell proliferation in the post-surgical stomach, dietary salt, and the effect of h pylo...
21886067 - Second-line levofloxacin-based triple therapy's efficiency for helicobacter pylori erad...
17006997 - Furazolidone-based triple therapy for h pylori gastritis in children.
8829417 - A comparison of meperidine and lidocaine for spinal anesthesia for postpartum tubal lig...
17302687 - Incidence and characteristics of appropriate and inappropriate therapies in recipients ...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2011-10-12
Journal Detail:
Title:  Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde     Volume:  227     ISSN:  1423-0267     ISO Abbreviation:  Ophthalmologica     Publication Date:  2012  
Date Detail:
Created Date:  2012-01-30     Completed Date:  2012-04-05     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0054655     Medline TA:  Ophthalmologica     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  100-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Affiliation:
Department of Ophthalmology, Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiogenesis Inhibitors / administration & dosage*,  adverse effects
Antibodies, Monoclonal, Humanized / administration & dosage*,  adverse effects
Diabetic Retinopathy / drug therapy*,  physiopathology
Drug Therapy, Combination
Female
Glucocorticoids / administration & dosage*,  adverse effects
Humans
Intravitreal Injections
Macular Edema / drug therapy*,  physiopathology
Male
Middle Aged
Prospective Studies
Retina / pathology
Tomography, Optical Coherence
Treatment Outcome
Triamcinolone Acetonide / administration & dosage*,  adverse effects
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Glucocorticoids; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab; 76-25-5/Triamcinolone Acetonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Magnetic phase diagrams based on static and dynamic magnetic behaviour in Ru-based superconducting f...
Next Document:  A Simultaneous Iris Angiography Technique in Pigmented Rabbits.